Chief Executive Officer, Kamat Pharmatech. Dr. Kamat founded Kamat Pharmatech in 2013 after 27 years in highly technical roles at companies such as Centocor, J&J, and Bristol Myers Squibb.

Recognized expert in lyophilization, nano-suspension technology, aseptic technology, and other sterile manufacturing processes. Selected products involved in development/launch/support:

Biologicals: Yervoy, Nulojix IV, Orencia (SC & IV), Erbitux, Remicade, Repro
Small molecules: Ixempra, Tequin, Ketorolac, Acyclovir
Cytotoxics: Taxol, BiCNU, Cytoxan, Carboplatin, Doxorubicin, Mutamycin, Etopophos
Unique: Kenalog (steroidal IM suspension)
Registered pharmacist in New Jersey and Pennsylvania. Course director for “Lyophilization Technology” in the US, Europe, and worldwide.